• DOI:10.1111/j.1538-7836.2008.03122.x
• Corpus ID: 1776526

Multiple anti‐atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance

@article{Pignatelli2008MultipleAT,
  title={Multiple anti‐atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance},
  author={Pasquale Pignatelli and Serena di Santo and Francesco Barill{\`a} and Carlo Gaudio and Francesco Violi},
  journal={Journal of Thrombosis and Haemostasis},
  year={2008},
  volume={6}
}

• P. Pignatelli, S. di Santo, +2 authors F. Violi
• Published 1 October 2008
• Biology
• Journal of Thrombosis and Haemostasis

Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902– 7. 7 Jang MJ, Kim NK, Chong SY, Kim HJ, Lee SJ, Kang MS, Oh D. Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J 2008; 49: 405–8. 8 Gao W, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders. Thromb Haemost 2004; 91: 1257–8. 9 Bongers TN, De Maat MP, Dippel DW, Uitterlinden AG, Leebeek FW. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost 2005; 3: 805. 10 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93–100. 11 Groot E, Hulstein JJ, Rison CN, de Groot PG, Fijnheer R. FRETSVWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 698–9. 12 Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146–8. 13 Mahdian R, Rayes J, Girma JP, Houllier A, Obert B, Meyer D, Veyradier A. Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples. Thromb Haemost 2006; 95: 1049–51. 14 Miyata T, Kokame K, Banno F, Shin Y, Akiyama M. ADAMTS13 assays and ADAMTS13-deficient mice. Curr Opin Hematol 2007; 14: 277–83. 15 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097–103. 16 Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Semin Hematol 2004; 41: 68–74.